This article is one of six invited review articles published in the Missing the Mark: Hepatic Encephalopathy supplement, which includes CME-accredited articles published in Clinical Gastroenterology and Hepatology (CGH) and the Journal of Hospital Medicine (JHM). The program is administered by AGA in collaboration with the Society of Hospital Medicine. Each article will provide an expert perspective on a topic related to practice gaps in the care and management of patients with cirrhosis and hepatic encephalopathy. This program is commercially supported by Salix.
Faculty:
Alpesh N. Amin MD
Department of Medicine, University of California, Irvine
Peter H. Nguyen MD
Department of Medicine, University of California, Irvine
Elliot B. Tapper MD
Division of Gastroenterology and Hepatology, University of Michigan
Learning Objectives:
- Upon completion of this CME exam, successful learners will be able to identify and treat early signs of cirrhosis or liver disease.
Released: June 11, 2022
Expires: May 31, 2026
Disclosures
Alpesh Amin, journal author, reported serving as PI or co-I of clinical trials sponsored by
NIH/NIAID, NeuroRx Pharma, Pulmotect, Blade Therapeutics, Novartis,
Takeda, Humanigen, Eli Lilly, PTC Therapeutics, OctaPharma, Fulcrum
Therapeutics, Alexion, unrelated to the present study; speaker and/or consultant
for BMS, Pfizer, BI, Portola, Sunovion, Mylan, Salix, Alexion, AstraZeneca,
Novartis, Nabriva, Paratek, Bayer, Tetraphase, Achogen, LaJolla,
Ferring, Seres, Spero, Eli Lilly, Millenium, PeraHealth, HeartRite, Aseptiscope,
Sprightly, unrelated to the present study.
Elliot Tapper, journal author, has served as a consultant to Norvartis, Axcella, and Allergan, has
served on advisory boards for Mallinckrodt, Bausch Health, Kaleido, Novo Nordisk,
and has received unrestricted research grants from Gilead and Valeant.
Peter Nguyen, journal author, has no conflict of interest
Funding:
- Alpesh Amin received funding from the MITRE, PCORI, Danaher through UCI for
research unrelated to this manuscript. - Elliot Tapper receives funding from the National Institutes of Health through NIDDK
(1K23DK117055).
All relevant financial disclosures have been mitigated.
Accreditation and designation statement
The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The AGA Institute designates this live activity for a maximum of 0.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planning partners must disclose all their financial relationships with ineligible companies held within the past 24 months. The AGA Institute implements a mechanism to identify and mitigate all conflicts of interest prior to delivering the educational activity to learners.
CME expiration date: May 31, 2026
